Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to RXRX. [ FAQ on what and how to ask] For non-RXRX questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
Employees: 600
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
CEO, President & Director
CFO & President of Recursion UK
Chief Technology Officer
Chief Scientific Officer
Chief Legal Officer & Corporate Secretary
Chief Communications Officer
Chief People and Impact Officer
Chief Business Officer
Senior Vice President of Clinical Development & Data Science
Chief Medical Officer
My Watchlist
